Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bisoprolol
2. Bisoprolol Fumarate (1:1) Salt, (+-)-isomer
3. Bisoprolol Fumarate (2:1) Salt, (+-)-isomer
4. Bisoprolol Hydrochloride
5. Bisoprolol Methanesulfonate Salt
6. Bisoprolol, (+-)-isomer
7. Bisoprolol, (-)-isomer
8. Bisoprolol, Fumarate (1:1) Salt
9. Bisoprolol, Fumarate (2:1) Salt
10. Cl 297939
11. Cl-297939
12. Cl297939
13. Concor
14. Emd 33512
15. Emd-33512
16. Emd33512
17. Fumarate, Bisoprolol
18. Hydrochloride, Bisoprolol
1. 104344-23-2
2. Zebeta
3. Bisoprolol Hemifumarate
4. Bisoprolol Monofumarate
5. Fondril
6. Maintate
7. Concor
8. 105878-43-1
9. Bisoprolol (fumarate)
10. Bisoprolol Hemifumarate Salt
11. U057cx04h0
12. Emd33512
13. Ta-4708
14. Cl-297939
15. 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol,(2e)-2-monobutenedioate
16. 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (2e)-2-butenedioate (1:1)
17. 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (2e)-2-butenedioate (1:1) (salt)
18. 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (e)-2-butenedioate (1:1) (salt)
19. Smr000471619
20. Emd-33512
21. Bisocard
22. Cardicor
23. Congescor
24. Sr-01000597980
25. Bisoprololfumarate
26. Concor Cor
27. 66722-45-0
28. Bisoprolol Fumarate (1:x)
29. Schembl41419
30. Mls001076669
31. Mls001401436
32. Unii-u057cx04h0
33. Chembl1200708
34. Bcpp000331
35. Hms1569a21
36. Hms2051i16
37. Hms2094o19
38. Hms2233f12
39. Hms3884o05
40. Pharmakon1600-01505704
41. Nsc759181
42. S1206
43. Akos005267174
44. Ac-5016
45. Bcp9000419
46. Ccg-100883
47. Ccg-213520
48. Nc00133
49. Nsc-759181
50. Hy-120829
51. B3994
52. Cs-0079270
53. Sw197151-3
54. 104b232
55. Q-200729
56. Sr-01000597980-4
57. Q27290514
58. 1-(4-((2-isopropoxyethoxy)methyl)phenoxy)-3-(isopropylamino)propan-2-ol Hemi-fumarate
59. 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)-2-propanol Fumaric Acid Salt
Molecular Weight | 441.5 g/mol |
---|---|
Molecular Formula | C22H35NO8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 14 |
Exact Mass | 441.23626707 g/mol |
Monoisotopic Mass | 441.23626707 g/mol |
Topological Polar Surface Area | 135 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 397 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Bisoprolol fumarate |
Drug Label | Bisoprolol fumarate is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent. The chemical name for bisoprolol fumarate is ()-1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol(E)-2-butenedioate... |
Active Ingredient | Bisoprolol fumarate |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg |
Market Status | Prescription |
Company | Teva Pharms; Unichem Pharms (usa); Aurobindo Pharma; Sandoz; Mylan |
2 of 4 | |
---|---|
Drug Name | Zebeta |
PubMed Health | Bisoprolol (By mouth) |
Drug Classes | Antianginal, Antihypertensive, Cardiovascular Agent |
Drug Label | ZEBETA (bisoprolol fumarate) is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent. The chemical name for bisoprolol fumarate is ()-1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol(E)-2-but... |
Active Ingredient | Bisoprolol fumarate |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg |
Market Status | Prescription |
Company | Teva Womens |
3 of 4 | |
---|---|
Drug Name | Bisoprolol fumarate |
Drug Label | Bisoprolol fumarate is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent. The chemical name for bisoprolol fumarate is ()-1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol(E)-2-butenedioate... |
Active Ingredient | Bisoprolol fumarate |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg |
Market Status | Prescription |
Company | Teva Pharms; Unichem Pharms (usa); Aurobindo Pharma; Sandoz; Mylan |
4 of 4 | |
---|---|
Drug Name | Zebeta |
PubMed Health | Bisoprolol (By mouth) |
Drug Classes | Antianginal, Antihypertensive, Cardiovascular Agent |
Drug Label | ZEBETA (bisoprolol fumarate) is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent. The chemical name for bisoprolol fumarate is ()-1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol(E)-2-but... |
Active Ingredient | Bisoprolol fumarate |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg |
Market Status | Prescription |
Company | Teva Womens |
Adrenergic beta-1 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
65
PharmaCompass offers a list of Bisoprolol Fumarate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bisoprolol Fumarate manufacturer or Bisoprolol Fumarate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bisoprolol Fumarate manufacturer or Bisoprolol Fumarate supplier.
PharmaCompass also assists you with knowing the Bisoprolol Fumarate API Price utilized in the formulation of products. Bisoprolol Fumarate API Price is not always fixed or binding as the Bisoprolol Fumarate Price is obtained through a variety of data sources. The Bisoprolol Fumarate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cardicor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cardicor, including repackagers and relabelers. The FDA regulates Cardicor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cardicor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cardicor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cardicor supplier is an individual or a company that provides Cardicor active pharmaceutical ingredient (API) or Cardicor finished formulations upon request. The Cardicor suppliers may include Cardicor API manufacturers, exporters, distributors and traders.
click here to find a list of Cardicor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cardicor DMF (Drug Master File) is a document detailing the whole manufacturing process of Cardicor active pharmaceutical ingredient (API) in detail. Different forms of Cardicor DMFs exist exist since differing nations have different regulations, such as Cardicor USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cardicor DMF submitted to regulatory agencies in the US is known as a USDMF. Cardicor USDMF includes data on Cardicor's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cardicor USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cardicor suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cardicor Drug Master File in Japan (Cardicor JDMF) empowers Cardicor API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cardicor JDMF during the approval evaluation for pharmaceutical products. At the time of Cardicor JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cardicor suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cardicor Drug Master File in Korea (Cardicor KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cardicor. The MFDS reviews the Cardicor KDMF as part of the drug registration process and uses the information provided in the Cardicor KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cardicor KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cardicor API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cardicor suppliers with KDMF on PharmaCompass.
A Cardicor CEP of the European Pharmacopoeia monograph is often referred to as a Cardicor Certificate of Suitability (COS). The purpose of a Cardicor CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cardicor EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cardicor to their clients by showing that a Cardicor CEP has been issued for it. The manufacturer submits a Cardicor CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cardicor CEP holder for the record. Additionally, the data presented in the Cardicor CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cardicor DMF.
A Cardicor CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cardicor CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cardicor suppliers with CEP (COS) on PharmaCompass.
A Cardicor written confirmation (Cardicor WC) is an official document issued by a regulatory agency to a Cardicor manufacturer, verifying that the manufacturing facility of a Cardicor active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cardicor APIs or Cardicor finished pharmaceutical products to another nation, regulatory agencies frequently require a Cardicor WC (written confirmation) as part of the regulatory process.
click here to find a list of Cardicor suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cardicor as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cardicor API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cardicor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cardicor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cardicor NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cardicor suppliers with NDC on PharmaCompass.
Cardicor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cardicor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cardicor GMP manufacturer or Cardicor GMP API supplier for your needs.
A Cardicor CoA (Certificate of Analysis) is a formal document that attests to Cardicor's compliance with Cardicor specifications and serves as a tool for batch-level quality control.
Cardicor CoA mostly includes findings from lab analyses of a specific batch. For each Cardicor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cardicor may be tested according to a variety of international standards, such as European Pharmacopoeia (Cardicor EP), Cardicor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cardicor USP).